Revenues soar in 1Q for Merge eFilm

Article

PACS vendor Merge eFilm reported a first quarter net sales increase of 41% to $8.64 million compared with $6.12 million in the previous year's quarter ended March 31, 2003. Operating income was $2.14 million, an increase of 45% compared with $1.48

PACS vendor Merge eFilm reported a first quarter net sales increase of 41% to $8.64 million compared with $6.12 million in the previous year's quarter ended March 31, 2003. Operating income was $2.14 million, an increase of 45% compared with $1.48 million in the previous year's quarter. Net income was $1.35 million compared with $1.32 million in 1Q 2003. Financial and operational gains reflected increasing popularity of the company's Fusion RIS/PACS. The company closed 17 deals for its Fusion RIS, PACS, or RIS/PACS during the quarter, increasing the total number of Fusion customers to 143, representing more than 290 healthcare facilities. Company executives anticipate continuing positive market conditions, with full-year 2004 guidance of 30% to 35% revenue growth year over year to a range of $37.5 to $39.5 million.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.